- Home
- SUPV vs AUTL Comparison
SUPV vs AUTL Comparison
Compare SUPV & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPV
- AUTL
- Stock Information
- Founded
- SUPV 1887
- AUTL 2014
- Country
- SUPV Argentina
- AUTL United Kingdom
- Employees
- SUPV N/A
- AUTL N/A
- Industry
- SUPV Commercial Banks
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SUPV Finance
- AUTL Health Care
- Exchange
- SUPV Nasdaq
- AUTL Nasdaq
- Market Cap
- SUPV 908.5M
- AUTL 863.6M
- IPO Year
- SUPV 2016
- AUTL 2018
- Fundamental
- Price
- SUPV $15.54
- AUTL $2.41
- Analyst Decision
- SUPV
- AUTL Strong Buy
- Analyst Count
- SUPV 0
- AUTL 3
- Target Price
- SUPV N/A
- AUTL $10.20
- AVG Volume (30 Days)
- SUPV 1.4M
- AUTL 1.9M
- Earning Date
- SUPV 11-25-2024
- AUTL 11-12-2024
- Dividend Yield
- SUPV 1.09%
- AUTL N/A
- EPS Growth
- SUPV 67.85
- AUTL N/A
- EPS
- SUPV 0.19
- AUTL N/A
- Revenue
- SUPV $435,663,160.00
- AUTL $10,091,000.00
- Revenue This Year
- SUPV N/A
- AUTL $1,000.24
- Revenue Next Year
- SUPV N/A
- AUTL $267.86
- P/E Ratio
- SUPV $17.21
- AUTL N/A
- Revenue Growth
- SUPV N/A
- AUTL 82.71
- 52 Week Low
- SUPV $3.33
- AUTL $2.44
- 52 Week High
- SUPV $16.27
- AUTL $7.45
- Technical
- Relative Strength Index (RSI)
- SUPV 84.84
- AUTL 30.41
- Support Level
- SUPV $11.77
- AUTL $2.44
- Resistance Level
- SUPV $16.27
- AUTL $2.97
- Average True Range (ATR)
- SUPV 0.84
- AUTL 0.17
- MACD
- SUPV 0.29
- AUTL -0.03
- Stochastic Oscillator
- SUPV 89.61
- AUTL 4.57
About SUPV Grupo Supervielle S.A. each Representing five Class B shares
Grupo Supervielle SA offers financial products & services. The company's segments include Personal and Business Banking, Corporate Banking, Bank Treasury, Consumer Finance, Insurance, Asset Management, and other services. The company provides services to individuals, small businesses, middle-market companies, and large corporates in Argentina. The company also offers mutual fund services.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.